Evidence Based Review on Daptomycin Use in the Treatment of Gram(+) Infections
Daptomycin is the only clinically used member of a cyclic lipopeptides class of antibiotics. Daptomycin has rapid bactericidal activity against not only rapidly growing, but also against slow growing bacterial cells including those in biofilms. Spectrum of daptomycin’s activity includes almost all c...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
2016-11-01
|
| Series: | Клиническая микробиология и антимикробная химиотерапия |
| Subjects: | |
| Online Access: | https://cmac-journal.ru/publication/2016/4/cmac-2016-t18-n4-p270/cmac-2016-t18-n4-p270.pdf |
| Summary: | Daptomycin is the only clinically used member of a cyclic lipopeptides class of antibiotics. Daptomycin has rapid bactericidal activity against not only rapidly growing, but also against slow growing bacterial cells including those in biofilms. Spectrum of daptomycin’s activity includes almost all clinically important Gram(+) microorganisms. At the moment daptomycin is approved for two indications — complicated skin and skin structure infections, and bloodstream infections — bacteremia and right-sided endocarditis, caused by S. aureus. But at the same time there are a lot of clinical and experimental data showing that daptomycin could be an useful drug for the treatment of variety of other infections, such as bones and joints infections, febrile neutropenia, etc, especially those caused by multi-resistant strains. |
|---|---|
| ISSN: | 1684-4386 2686-9586 |